Heath R C, Gossain V V, Rovner D R
Department of Medicine, Michigan State University, East Lansing 48824.
South Med J. 1988 May;81(5):601-5. doi: 10.1097/00007611-198805000-00015.
To determine whether a therapeutic dose of iodine 131 affects the results of 24-hour radioactive iodine uptake (RAIU) testing, we reviewed records of hyperthyroid patients previously treated with 131I at Michigan State University and its affiliated hospitals. We identified 26 patients who had had clinical evaluation and determination of the serum thyroxine (T4) level, triiodothyronine resin uptake (T3RU), and RAIU (using 131I) within two weeks before and several months after the therapeutic dose of 131I. Before treatment, all patients had clinical hyperthyroidism, with an elevated T4 level and increased T3RU and RAIU. After treatment with 131I, eight patients (31%) had an RAIU that was discordant with their clinical and biochemical (T4 and T3RU) assessment. In six patients (23%) of the RAIU was inappropriately high, and in two patients (8%) it was inappropriately low. Since we did not identify any other factors known to interfere with the results of RAIU testing, we conclude that a therapeutic dose of 131I, may by itself increase or decrease a subsequent RAIU determination; therefore, after treatment with 131I, RAIU is not a good diagnostic index of thyroid activity.
为了确定治疗剂量的碘131是否会影响24小时放射性碘摄取(RAIU)试验的结果,我们回顾了密歇根州立大学及其附属医院中先前接受过131I治疗的甲状腺功能亢进患者的记录。我们确定了26例患者,他们在接受131I治疗剂量之前两周内以及之后几个月内进行了临床评估,并测定了血清甲状腺素(T4)水平、三碘甲状腺原氨酸树脂摄取率(T3RU)和RAIU(使用131I)。治疗前,所有患者均有临床甲状腺功能亢进,T4水平升高,T3RU和RAIU增加。用131I治疗后,8例患者(31%)的RAIU与其临床和生化(T4和T3RU)评估结果不一致。在6例患者(23%)中,RAIU异常升高,2例患者(8%)中RAIU异常降低。由于我们未发现任何已知会干扰RAIU试验结果的其他因素,我们得出结论,治疗剂量的131I本身可能会增加或降低随后的RAIU测定结果;因此,131I治疗后,RAIU不是甲状腺活性的良好诊断指标。